Welcome to our home for news – the latest headlines, all in one place. Click through to view a selection of our media coverage, industry news, videos and more.
First prescriptions for Sofdra™ (sofpironium) topical gel, 12.45% have shipped to patients after having successfully been diagnosed via telemedicine and cleared insurance approvals. Following sales force deployment, a wider digital program will begin in Q2 2025.
Botanix Founder and Board Executive Director Matt Callahanwill be a featured presenter at the Bell Potter Healthcare Conference 2024 on Tuesday, 19 November. A copy of the presentation being used is attached to the ASX press release.
https://botanixpharma.com/wp-content/uploads/BOT_Website.png7361104Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2024-11-19 02:40:082024-11-19 02:40:08Botanix presentation at Bell Potter Healthcare Conference
Ascent Health, second largest Payer (insurer) organisation in the US, will now cover Sofdra™ (sofpironium) topical gel, 12.45%. Ascent represents approximately 65 million (or nearly 40%) of US commercial lives.
Quarterly Activity Report and 4C Quarterly Cash Flow Report released. At quarter end, Botanix held A$68.67 million cash with no debt (other than typical trade creditors), which will fund operations as it ramps up manufacturing and sales activity of its Sofdra product.
While in Australia last month, Botanix CEO Dr Howie McKibbon spoke with Bell Direct’s Grady Wulff about the Company’s FDA-approved product, Sofdra™, the competitive landscape in dermatology, and the outlook for Botanix over the next 12 months.
Take a look:
https://botanixpharma.com/wp-content/uploads/From-The-Helm.png8501600Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2024-10-10 21:54:582024-10-10 21:55:00From The Helm | Interview with CEO Dr Howie McKibbon
Botanix CEO Howie McKibbon recently visited Australia to meet with investors, and to present at the ASX Small and Mid-Cap Conference and the E&P Small Cap Healthcare Conference.
During his visit, he was interviewed in the Ausbiz studio to discuss the Company’s comprehensive commercialisation plans for Sofdra™. Take a look:
https://botanixpharma.com/wp-content/uploads/Howie-ausbiz.png8501600Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2024-10-07 01:45:042024-10-07 01:45:04Ausbiz | Interview with Howie McKibbon
First Sofdra™ prescriptions as commercialization ramps up
/in ASX Releases, Featured, Latest News, News /by Haley ChartresFirst prescriptions for Sofdra™ (sofpironium) topical gel, 12.45% have shipped to patients after having successfully been diagnosed via telemedicine and cleared insurance approvals. Following sales force deployment, a wider digital program will begin in Q2 2025.
View release.
Botanix presentation at Bell Potter Healthcare Conference
/in ASX Releases, Featured, Latest News, News /by Haley ChartresBotanix Founder and Board Executive Director Matt Callahanwill be a featured presenter at the Bell Potter Healthcare Conference 2024 on Tuesday, 19 November. A copy of the presentation being used is attached to the ASX press release.
View ASX release.
Botanix adds Payer coverage representing ~65 million commercial lives
/in ASX Releases, Featured, Latest News, News /by Haley ChartresAscent Health, second largest Payer (insurer) organisation in the US, will now cover Sofdra™ (sofpironium) topical gel, 12.45%. Ascent represents approximately 65 million (or nearly 40%) of US commercial lives.
View release.
Botanix Releases Quarterly Reports
/in ASX Releases, Featured, Latest News, News /by Haley ChartresQuarterly Activity Report and 4C Quarterly Cash Flow Report released. At quarter end, Botanix held A$68.67 million cash with no debt (other than typical trade creditors), which will fund operations as it ramps up manufacturing and sales activity of its Sofdra product.
View Report.
From The Helm | Interview with CEO Dr Howie McKibbon
/in Featured, Latest News, News, Videos /by Haley ChartresWhile in Australia last month, Botanix CEO Dr Howie McKibbon spoke with Bell Direct’s Grady Wulff about the Company’s FDA-approved product, Sofdra™, the competitive landscape in dermatology, and the outlook for Botanix over the next 12 months.
Take a look:
Ausbiz | Interview with Howie McKibbon
/in Featured, Latest News, News, Videos /by Haley ChartresBotanix CEO Howie McKibbon recently visited Australia to meet with investors, and to present at the ASX Small and Mid-Cap Conference and the E&P Small Cap Healthcare Conference.
During his visit, he was interviewed in the Ausbiz studio to discuss the Company’s comprehensive commercialisation plans for Sofdra™. Take a look: